Lannett Signs Patent Sublicense Deal With Ypsomed for Pen Injector Device; Shares Rise - Marketscreener.com

2 years ago 34

Homepage Equities United States Nyse Lannett Company, Inc. News Summary     LCI   US5160121019 (LCI) Add to my list   Report Real-time Estimate Cboe BZX  -  11:00 2022-11-07 americium EST 0.4940 USD   +7.37% 10:50a Lannett Signs Patent Sublicense Deal With Ypsomed for Pen Injector Device; Shares Rise MT 06:53a Lannett announces patent licenses for the pen injector transportation instrumentality to beryllium utilized for its insulin glargine and insulin aspart improvement program PR 11/03 LANNETT CO INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) AQ Summary Quotes Charts News Ratings Calendar Company Financials Consensus Revisions Funds   Summary Most relevant All News Analyst Reco. Other languages Press Releases Official Publications Sector news 11/07/2022 | 10:50am EST MT Newswires 2022 Stocks mentioned successful the article Change Last 1st jan. LANNETT COMPANY, INC.  7.26% 0.4935 -71.60% SANOFI  -1.62% 86.51 -0.79% YPSOMED HOLDING AG  1.22% 166.4 -11.53% All quality about LANNETT COMPANY, INC. 10:50a Lannett Signs Patent Sublicense Deal With Ypsomed for Pen Injector Device; Shares Rise MT 06:53a Lannett announces patent licenses for the pen injector transportation instrumentality to beryllium utilized for i.. PR 11/03 LANNETT CO INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS.. AQ 11/02 Lannett : Fiscal Q1 Earnings Snapshot AQ 11/02 Transcript : Lannett Company, Inc., Q1 2023 Earnings Call, Nov 02, 2022 CI 11/02 Earnings Flash (LCI) LANNETT COMPANY Posts Q1 Loss $-0.42 MT 11/02 Earnings Flash (LCI) LANNETT COMPANY Reports Q1 Revenue $75.1M MT 11/02 Lannett reports amended than expected fiscal results for fiscal 2023 first-quarter; r.. PR 11/02 Lannett Company, Inc. Reports Asset Impairment Charges for the First Quarter Ended Sept.. CI 11/02 Lannett Company, Inc. Reiterates Earnings Guidance for the Fiscal Year 2023 CI More news Analyst Recommendations on LANNETT COMPANY, INC. 2021 Lannett : Roth Capital Adjusts Lannett's Price Target to $6 from $7, Keeps Neutr.. MT 2021 Lannett : Roth Capital Adjusts Lannett PT to $7 From $7.50, Maintains Neutral Ra.. MT 2020 Lannett : S&P Affirms Lannett Co 'B-Minus' Issuer Credit Rating On Debt Retireme.. MT More recommendations Financials (USD) Sales 2023 290 M - - Net income 2023 -68,4 M - - Net Debt 2023 - - - P/E ratio 2023 -0,31x Yield 2023 - Capitalization 18,9 M 18,9 M - Capi. / Sales 2023 0,07x Capi. / Sales 2024 0,06x Nbr of Employees 564 Free-Float 85,6% More Financials Chart LANNETT COMPANY, INC. Duration : Period : Full-screen chart Technical investigation trends LANNETT COMPANY, INC. Short Term Mid-Term Long Term Trends Neutral Bearish Bearish Technical analysis Income Statement Evolution More Financials Consensus Sell Buy Mean consensus HOLD Number of Analysts 2 Last Close Price 0,46 $ Average people price 1,00 $ Spread / Average Target 117% Consensus EPS Revisions More Estimates Revisions Managers and Directors Timothy C. Crew Chief Executive Officer & Director John Kozlowski Corporate Controller Patrick G. LePore Independent Non-Executive Chairman Robert Ehlinger Chief Information Officer David A. Drabik Lead Independent Director More astir the company Sector and Competitors 1st jan. Capi. (M$) LANNETT COMPANY, INC. -71.60% 19 SUN PHARMACEUTICAL INDUSTRIES LTD. 22.96% 30 403 OTSUKA HOLDINGS CO., LTD. 10.39% 16 969 SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. -24.99% 12 531 CIPLA LIMITED 21.40% 11 271 ONO PHARMACEUTICAL CO., LTD. 18.52% 11 231 More Results

1. Homepage
2. Technology
3. Lannett Signs Patent Sublicense Deal With Ypsomed for Pen Injector Device; Shares Rise - Marketscreener.com